Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Stearic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.81 |
| ▸ | PPARG | P37231 | 7/20 | 0.81 |
| ▸ | PPARD | Q03181 | 7/20 | 0.81 |
| ▸ | PPARA | Q07869 | 7/20 | 0.81 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.81 |
| ▸ | TSHR | P16473 | 4/20 | 0.81 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.81 |
| ▸ | FABP4 | P15090 | 3/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.81 |
| ▸ | TLR2 | O60603 | 2/20 | 0.81 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.81 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.81 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.81 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.81 |
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
| ▸ | ESR1 | P03372 | 1/20 | 0.81 |
| ▸ | PDE4A | P27815 | 1/20 | 0.81 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Stearic Acid SCHEMBL2116876 | 0.98 | GPR84 (0.85) | GPR84PPARGPPARDPPARAHDAC11 | |
| Stearic Acid SCHEMBL20548036 | 0.95 | GPR84 (0.81) | GPR84PPARGPPARDPPARAHDAC11 | |
| Stearic Acid SCHEMBL8845358 | 0.95 | GPR84 (0.81) | GPR84PPARGPPARDPPARAHDAC11 | |
| Tridecanoate SCHEMBL1994545 | 0.93 | GPR84 (0.94) | GPR84PPARGPPARDPPARAHDAC11 | |
| Heneicosanoic Acid SCHEMBL7907716 | 0.93 | GPR84 (0.94) | GPR84PPARGPPARDPPARAHDAC11 | |
| Dodecanoate SCHEMBL23581128 | 0.93 | GPR84 (0.94) | GPR84PPARGPPARDPPARAHDAC11 | |
| Palmitic Acid SCHEMBL539137 | 0.93 | GPR84 (0.94) | GPR84PPARGPPARDPPARAHDAC11 | |
| Heptanoate SCHEMBL19994751 | 0.93 | GPR84 (0.94) | GPR84PPARGPPARDPPARAHDAC11 | |
| Nonanoate SCHEMBL4152676 | 0.93 | GPR84 (0.94) | GPR84PPARGPPARDPPARAHDAC11 | |
| Pentadecanoic Acid SCHEMBL6712161 | 0.93 | GPR84 (0.94) | GPR84PPARGPPARDPPARAHDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399696-B2 | Functionalized biodegradable triclosan monomers and oligomers for controlled release | BEZWADA BIOMEDICAL, LLC (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120289614-A1 | FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE | BEZWADA BIOMEDICAL, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-8232422-B2 | Functionalized biodegradable triclosan monomers and oligomers for controlled release | BEZWADA BIOMEDICAL, LLC (US) | 2012-07-31 | — | — | US | disclosed |
| US-20120095114-A1 | FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE | BEZWADA BIOMEDICAL, LLC (US) | 2012-04-19 | — | — | US | disclosed |
| US-8053591-B2 | Functionalized biodegradable triclosan monomers and oligomers for controlled release | BEZWADA BIOMEDICAL, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| US-20090105352-A1 | FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE | BEZWADA BIOMEDICAL, LLC (US) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105352-A1 | FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE | LTN1, PARN, TLR3 | GPR84 660/4885PPARG 4131/4885PPARD 3587/4885 |
| US-20120095114-A1 | FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE | LTN1, PARN, TLR3 | GPR84 660/4885PPARG 4131/4885PPARD 3587/4885 |
| US-20120289614-A1 | FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE | LTN1, PARN, TLR3 | GPR84 660/4885PPARG 4131/4885PPARD 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.